Ask your care team what changed when a different pharmacy name appears on your prescription. Request the preparation and matching directions before relying on familiar details. [1]
Use the Omnia TeleHealth review and Omzo review to organize enrollment questions. Request the prescribed preparation and intended dispenser together.
What an FDA equivalence evaluation means
The Orange Book evaluates therapeutic equivalence for approved multisource prescription products: an expectation of the same clinical effect and safety under labeled conditions. They are scientific evaluations, not a nationwide instruction to substitute. FDA also says exclusion from the book does not itself prove that a product is unsafe, ineffective or therapeutically unequal. [1]
Compounded drugs lack FDA approval and premarket review of safety, effectiveness and quality. FDA cautions that online purchasers may not know the compounder’s identity or regulatory status. [2]
Read the approval article. Ask the clinician and pharmacist to compare your selected prescriptions. [2]
Nonapproval does not mean no oversight
Sections 503A and 503B provide different conditional exemptions from specified federal requirements. Other requirements still apply. FDA’s summary is not an exhaustive list. A facility’s category alone does not establish that a selected preparation meets every applicable condition. [3]
Use the 503A and 503B article and pharmacy-vetting guide to organize questions about the named facility. Ask which rules apply to your prescription rather than treating a website badge as the answer.
Check the new vial and its directions together
FDA’s compounded injectable semaglutide alert describes varying concentrations, containers and measuring instructions. It reports dosing errors involving confusion between milligrams, milliliters and syringe units. Ask the prescriber or pharmacist to confirm the prescribed dose, the new concentration and matching syringe markings before use. Do not work out a conversion from an old label or another patient’s instructions. [4]
Keep the new label and written instructions together. The vial-contents, syringe and storage guides cover questions to take to the care team. Ask which lot documents are available and how to interpret them; do not assume they have been independently verified.
Appearance studies measured associations
A 2014 observational study examined generic cardiovascular medicines after a heart attack. It defined nonpersistence as stopping the index medicine for at least one month. Changed pill color was associated with higher adjusted odds of nonpersistence: odds ratio 1.34, 95% confidence interval 1.12–1.59. This was an association, not proof that color caused treatment to stop; clinical outcomes were not assessed. [5]
A separate 2013 nested case-control study examined antiepileptic medicines. It defined nonpersistence as failing to refill within five days after the previous supply ran out. Color discordance was associated with nonpersistence, adjusted odds ratio 1.27, 95% confidence interval 1.04–1.55. [6]
A historical GLP-1 cohort is not today’s baseline
A 2024 claims study followed 4,066 commercially insured adults with obesity and without diabetes who started GLP-1 therapy in 2021. At one year, 32.3% met its persistence definition: no gap of 60 days or longer, allowing GLP-1 drug switching. That is a historical cohort result, not a current class-wide rate. The abstract does not establish an absence of pharmacy changes or measure their effect. [7]
Get the change explained before comparing offers
Request the pharmacy name, ingredient and preparation, concentration, quantity, intended supply period and written directions. Ask who answers medication questions and how future changes will be communicated. Separately confirm the total charge and cancellation terms. These questions do not assume a change has been hidden or that one preparation matches another.
Use the seller reviews and methodology to compare published information. Start with the compounded semaglutide board when comparing offers; ask the clinician and dispensing pharmacist about the selected medicine.